Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A phase 3 randomized trial

被引：0
|
作者：
Bissonnette, R. [1 ]
Iversen, L. [2 ]
Sofen, H. [3 ]
Griffiths, C. E. M. [4 ,5 ]
Foley, P. [6 ]
Romiti, R. [7 ]
Bachinsky, M. [8 ]
Rottinghaus, S. T. [8 ]
Tan, H. [8 ]
Proulx, J. [8 ]
Valdez, H. [9 ]
Gupta, P. [8 ]
Mallbris, L. [10 ]
Wolk, R. [8 ]
机构：
[1] Innovaderm Res, Montreal, PQ, Canada
[2] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
[3] Univ Calif Los Angeles, Sch Med, Dept Med Dermatol, Los Angeles, CA USA
[4] Univ Manchester, Dermatol Ctr, Manchester, Lancs, England
[5] Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[6] Univ Melbourne, Skin & Canc Fdn Inc, Carlton, Vic 3053, Australia
[7] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, Brazil
[8] Pfizer Inc, Groton, CT 06340 USA
[9] Pfizer Inc, New York, NY USA
[10] Pfizer Inc, Collegeville, PA USA
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2015年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：37 / 37
页数：1
相关论文
共 50 条
  • [1] Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
    Bissonnette, R.
    Iversen, L.
    Sofen, H.
    Griffiths, C. E. M.
    Foley, P.
    Romiti, R.
    Bachinsky, M.
    Rottinghaus, S. T.
    Tan, H.
    Proulx, J.
    Valdez, H.
    Gupta, P.
    Mallbris, L.
    Wolk, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (05) : 1395 - 1406
  • [2] Bimekizumab efficacy in patients with moderate to severe plaque psoriasis during the randomized withdrawal and retreatment phase of BE READY, a phase 3 trial
    Blauvelt, Andrew
    Wu, Jashin J.
    Reich, Kristian
    Gooderham, Melinda
    Lebwohl, Mark
    White, Katy
    Cross, Nancy
    Cioffi, Christopher
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB139 - AB139
  • [3] Impact of withdrawal and retreatment on immunogenicity of guselkumab in patients with moderate-to-severe plaque psoriasis
    Zhu, Yaowei
    Marini, Joseph C.
    Wasfi, Yasmine
    Song, Michael
    Randazzo, Bruce
    Shen, Yaung-Kaung
    Li, Shu
    Zhou, Honghui
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB161 - AB161
  • [4] Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
    Bachelez, Herve
    van de Kerkhof, Peter C. M.
    Strohal, Robert
    Kubanov, Alexey
    Valenzuela, Fernando
    Lee, Joo-Heung
    Yakusevich, Vladimir
    Chimenti, Sergio
    Papacharalambous, Jocelyne
    Proulx, James
    Gupta, Pankaj
    Tan, Huaming
    Tawadrous, Margaret
    Valdez, Hernan
    Wolk, Robert
    LANCET, 2015, 386 (9993): : 552 - 561
  • [5] Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
    Di Lernia, V.
    Bardazzi, F.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 533 - 539
  • [6] The management of moderate-to-severe chronic plaque psoriasis
    Tonini, Annalisa
    Panduri, Salvatore
    D'Erme, Angelo M.
    Papadia, Francesca
    Romaneli, Marco
    Krueger, James G.
    Chiricozzi, Andrea
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2017, 152 (05): : 447 - 457
  • [7] Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials
    Menter, M. Alan
    Papp, Kim A.
    Cather, Jennifer
    Leonardi, Craig
    Pariser, David M.
    Krueger, James G.
    Wohlrab, Johannes
    Amaya-Guerra, Mario
    Kaszuba, Andrzej
    Nadashkevich, Oleg
    Tsai, Tsen-Fang
    Gupta, Pankaj
    Tan, Huaming
    Valdez, Hernan
    Mallbris, Lotus
    Tatulych, Svitlana
    JOURNAL OF DRUGS IN DERMATOLOGY, 2016, 15 (05) : 568 - 580
  • [8] Predictors of response to tofacitinib or etanercept in a phase 3 randomized, noninferiority study in patients with moderate to severe chronic plaque psoriasis
    Lambert, Jo
    Strohal, Robert
    de la Cruz, Claudia
    Thaci, Diamant
    Bachelez, Herve
    Iversen, Lars
    Rottinghaus, Scott
    Tallman, Anna
    Tan, Huaming
    Berstein, Gabriel
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB263 - AB263
  • [9] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    Gordon, K. B.
    Blauvelt, A.
    Papp, K. A.
    Langley, R. G.
    Luger, T.
    Ohtsuki, M.
    Reich, K.
    Amato, D.
    Ball, S. G.
    Braun, D. K.
    Cameron, G. S.
    Erickson, J.
    Konrad, R. J.
    Muram, T. M.
    Nickoloff, B. J.
    Osuntokun, O. O.
    Secrest, R. J.
    Zhao, F.
    Mallbris, L.
    Leonardi, C. L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04): : 345 - 356
  • [10] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    Egeberg, Alexander
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21): : 2101 - 2102
12345